1.63
前日終値:
$1.62
開ける:
$1.62
24時間の取引高:
96,718
Relative Volume:
1.96
時価総額:
$80.23M
収益:
$596.60K
当期純損益:
$-11.72M
株価収益率:
-6.8315
EPS:
-0.2386
ネットキャッシュフロー:
$-9.51M
1週間 パフォーマンス:
+13.59%
1か月 パフォーマンス:
+25.38%
6か月 パフォーマンス:
+13.19%
1年 パフォーマンス:
+21.26%
Medicinova Inc Stock (MNOV) Company Profile
Compare MNOV vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
MNOV
Medicinova Inc
|
1.63 | 67.43M | 596.60K | -11.72M | -9.51M | -0.2386 |
|
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-10 | 開始されました | Maxim Group | Buy |
| 2019-03-25 | 再開されました | B. Riley FBR | Buy |
| 2018-03-28 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | 開始されました | Credit Suisse | Outperform |
| 2013-01-04 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2012-05-24 | ダウングレード | MLV & Co | Buy → Hold |
| 2011-10-18 | 繰り返されました | MLV Capital | Buy |
| 2011-06-22 | 開始されました | Global Hunter Securities | Buy |
| 2010-05-12 | 開始されました | Wedbush | Outperform |
| 2008-11-12 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2008-05-15 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | 開始されました | Punk, Ziegel & Co | Buy |
すべてを表示
Medicinova Inc (MNOV) 最新ニュース
MediciNova stock gains as price moves above 200-day line - AD HOC NEWS
MediciNova Inc (NASDAQ: MNOV) Share Price, MNOV Stock News, MNOV Share Price & Updates - Kalkine
MediciNova Ends Standby Equity Financing Agreement - TipRanks
MediciNova (MNOV) ends $30M stock-sale deal after tapping only a fraction of it - Stock Titan
MediciNova Updates Executive Contracts, Enhancing Change-in-Control Protection - TipRanks
Medicinova (MNOV) Outlook: Closes 8.57% Higher at $1.52 in the Latest Reading; Market Levels: $1.44 and $1.60 Define the Nearby Reference Levels in Latest TradingVolatility Smile - vinanet.vn
Medicinova (MNOV) Financial Update: Profit Per Share Surpasses Its Benchmark in the Current Update; After Results: The Market Price Declines 2.90% at the CloseEPS Growth Rate - vinanet.vn
MediciNova, Inc. (NASDAQ:MNOV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Form 8K MediciNova Inc For: 19 August By Investing.com - Investing.com Nigeria
MediciNova updates executive employment agreements for CEO and CMO By Investing.com - Investing.com South Africa
MediciNova updates executive employment agreements for CEO and CMO - Investing.com
FY2026 EPS Estimates for MediciNova Lowered by HC Wainwright - MarketBeat
FY2028 EPS Estimates for MediciNova Lowered by HC Wainwright - MarketBeat
Medicinova (MNOV) Holds Steady at $1.31 as Clinical-Stage Biotech Trades Within RangeWave Alternation - Vinanet
MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
MediciNova (NASDAQ:MNOV) Announces Quarterly Earnings Results - MarketBeat
MediciNova Inc reports results for the quarter ended June 30Earnings Summary - TradingView
MediciNova: Q2 Earnings Snapshot - AOL.com
MNOV: Q2 2026 revenue grew and net loss narrowed, with cash reserves supporting operations into 2027 - TradingView
MNOV Q2'26 Earnings: EPS estimate is (0.06) USD - TradingView
MNOV Q1 2026 Earnings: Narrower-Than-Expected Loss, But Stock Slips 1.49%High Estimate Range - vinanet.vn
MediciNova Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
MNOV Q2'26 Earnings: revenue estimate is 75.00K USD - TradingView
MediciNova Inc (MNOV) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
MediciNova (MNOV) Projected to Release Earnings on Thursday - MarketBeat
MNOV Q1 2026 Earnings: Narrower-than-Expected Loss Underscores Operational DisciplineNon-GAAP Earnings - vinanet.vn
Medicinova (MNOV) Slips 0.75% to $1.33; Key Support at $1.26 in FocusInside Day Breakout - vinanet.vn
Price to book forward of MediciNova, Inc. – NASDAQ:MNOV - tradingview.com
Medicinova Inc (MNOV) Edges Higher on Modest Volume, Testing Key ResistanceDonchian Channel - vinanet.vn
MNOV Q1 2026 Earnings: EPS Beat Driven by Reduced Operating Costs, Stock Declines 3%EPS Miss Report - vinanet.vn
MediciNova, Inc. Revenue Breakdown – NASDAQ:MNOV - TradingView
MediciNova Inc (MNOV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MediciNova Inc (MNOV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MediciNova Inc (MNOV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
MediciNova Inc (MNOV) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Medicinova Inc (MNOV) Edges Higher in Low-Volume Trading, Holds Near Key SupportFast Moving Stocks - vinanet.vn
Enterprise value to EBIT forward of MediciNova, Inc. – NASDAQ:MNOV - TradingView
Price to sales forward of MediciNova, Inc. – NASDAQ:MNOV - TradingView
Enterprise value to EBIT forward of MediciNova, Inc. – TSE:4875 - TradingView
MediciNova stock trades steady as investors weigh recent losses and pipeline progress - Ad-hoc-news.de
Price to sales forward of MediciNova, Inc. – TSE:4875 - TradingView
MediciNova stock trades steady as pipeline progress contrasts with lower recent revenues - Ad-hoc-news.de
Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO) - The Globe and Mail
MediciNova, Inc. (NASDAQ:MNOV) Sees Significant Increase in Short Interest - MarketBeat
H.C. Wainwright Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $10 - Moomoo
MediciNova reaches 200-patient enrollment in ALS study - Investing.com
MediciNova reaches 200-patient enrollment in ALS study By Investing.com - Investing.com Nigeria
ALS patients ineligible for trials join MediciNova's 200-person study - Stock Titan
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients - GlobeNewswire
Medicinova Inc (MNOV) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):